Market News

Gilead’s Yescarta Immunotherapy Wins FDA Approval

Kite, a unit of biopharmaceutical company Gilead Sciences (NASDAQ: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved its Yescarta CAR T-cell immunotherapy. The therapy is a first-of-its-kind treatment for adult patients with relapsed or refractory large B-cell lymphoma (LBCL). These patients include individuals who have received first-line therapy in the last 12 months. 

Supporting Data 

The U.S. regulator’s decision was based on ZUMA-7, a randomized, open-label Phase 3 study. It was designed to evaluate the safety and efficacy of Yescarta versus the current standard of care (SOC) for second-line therapy. Around 359 patients participated in the study, which showed that the primary endpoint is event-free survival (EFS). 

Annually, over 18,000 people are diagnosed with LBCL in the U.S., with about 30%-40% of patients requiring second-line treatment. 

Official Comments 

On reaching the milestone, Kite CEO Christi Shaw said, “Today’s FDA approval brings that hope to more patients by enabling the power of CAR T-cell therapy to be used earlier in the treatment journey.” 

Smart Score 

According to TipRanks’ Smart Score system, Gilead gets a 7 out of 10, which indicates that the stock is likely to perform in line with market averages. 

Wall Street’s Take 

Recently, Robert W. Baird analyst Brian Skorney maintained a Hold rating on Gilead and a price target of $63 (5.58% upside potential). 

The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating. That’s based on eight analysts suggesting a Buy, nine analysts recommending a Hold, and one analyst suggesting a Sell. The average Gilead price target of $71.24 implies 19.39% upside potential to current levels. Shares have decreased 6.1% over the past year.

Download the TipRanks mobile app now 

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. 

Read full Disclaimer & Disclosure 

Related News: 
GameStop Contemplates Stock Split; Shares Soar 
Tesla Doubling Down on Deals for Nickel Supplies 
Walgreens Slumps on Cautious Guidance Despite Q2 Beat

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More